Users' guides to the medical literature: XIII. How to use an article on economic analysis of clinical practice: A. Are the results of the study valid?

JAMA

Volumn 277, Issue 19, 1997, Pages 1552-1557

  Drummond, Michael F ^a   Richardson, W Scott ^b   O'Brien, Bernie J ^c   Levine, Mitchell ^c   Heyland, Daren ^d   Guyatt, Gordon H ^e  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c ST JOSEPH S HOSPITAL   (Canada)

^d ROYAL ALEXANDRA HOSPITAL   (Canada)

^e MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPUTER NETWORK; HEALTH ECONOMICS; INFORMATION SCIENCE; INFORMATION SYSTEM; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRIVATE PRACTICE;

EID: 0003702642     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.19.1552     Document Type: Article

References (32)

1. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
2. Mark DB, Hlatky MA, Califf RM, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418-1424.
3. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. Cost-effectiveness of model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med. 1995;10:321-330.
4. Goel V, Naylor CD. Potential cost-effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction. Can J Cardiol. 1992;8:31-38.
5. Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practices. JAMA. 1989; 262:2879-2886.
6. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1990; 113:147-154.
7. Elixhauser A, Luce BR, Taylor WR, Reblando J. Health care CBA/CEA: an update on the growth and composition of the literature. Med Care. 1993; 31(suppl):JS1-JS11, JS18-JS149.
8. Backhouse ME, Backhouse RJ, Edey SA. Economic evaluation bibliography. Health Econ. 1992; 1(suppl):1-236.
9. Russell LB, Gold MR, Seigel JE, Daniels N, Weinstein MC, for the Panel on Cost-Effectiveness in Health and Medicine. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996; 276:1172-1177.
10. Richardson WS, Detsky AS, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, VII: how to use a clinical decision analysis, A: are the results of the study valid? JAMA. 1995;273:1292-1295.
11. Wilson MC, Hayward RSA, Tunis SR, Bass EB, Guyatt G, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, VIII: how to use clinical practice guidelines, B: what are the recommendations and will they help you in caring for your patient? JAMA. 1995;274:1630-1632.
12. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, England: Oxford University Press; 1987.
13. Luce BR, Elixhauser A. Standards for Socio-economic Evaluation of Health Care Products and Services. Berlin, Germany: Springer Verlag; 1990.
14. Kamlet MS. A Framework for Cost-Utility Analysis of Government Health Care Programs: Report to the Office of Disease Prevention and Health Promotion. Washington, DC: Public Health Service, US Dept of Health and Human Services in cooperation with the Foundation of Health Services Research; 1990.
15. Topol EJ, Burek K, O'Neill WW, et al. A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reper-fusion. N Engl J Med. 1988;318:1083-1088.
16. Weisbrod BA, Test MA, Stein LI. Alternative to mental hospital treatment, II: economic benefit-cost analysis. Arch Gen Psychiatry. 1980;37:400-405.
17. Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making. 1989;9:142-149.
18. Mugford M, Kingford J, Chalmers I. Reducing the incidence of infection after caesarian section: implications of prophylaxis with antibiotics for hospital resources. BMJ. 1989;299:1003-1006.
19. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1989;149:2061-2065.
20. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with the synthetic prostaglandin misoprostol: a multicentre, double-blind, placebo-controlled trial. Lancet. 1988; 2:1277-1280.
21. Schulman KA, Lynn LA, Click HA, Eisenberg JM. Cost-effectiveness of low dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991;114:798-802.
22. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet. 1994;343:871-881.
23. Finkler SA. The distinction between cost and charges. Ann Intern Med. 1982;96:102-109.
24. Cohen DJ, Breall JA, Kalon KLH, et al. Economics of elective coronary revascularization: comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting and bypass surgery. J Am Coll Cardiol. 1993;22:1052-1059.
25. Sifton DW. 1993 Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Medical Economics Data; 1993.
26. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmaco Econ. 1996; 9:113-120.
27. Parsonage M, Neuberger H. Discounting and health benefits. Health Econ. 1992;1:71-76.
28. Cairns J. Discounting and health benefits: another perspective. Health Econ. 1992;1:76-79.
29. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: issues in the design and analysis of stochastic economic appraisals. Med Care. 1994;32:150-163.
30. Udvarhelyi IS, Colditz GA, Rai A, Epstein MA. Cost-effectiveness and cost-benefit analysis in the medical literature: are the methods being used correctly? Ann Intern Med. 1992;116:238-244.
31. Epstein MA. Cost-effectiveness of antihyperlipidemic therapy in the prevention of coronary heart disease: the case of cholestyramine. JAMA. 1987;258:2381-2387.
32. Goldman L, Sia STB, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med. 1988;319:152-157.